期刊文献+

奥沙西罗亲水凝胶骨架片制备及体外释药特性研究 被引量:4

Preparation of Oxaceprol matrix tablet and study of factors influencing its releasing behavior
下载PDF
导出
摘要 目的制备奥沙西罗亲水凝胶骨架缓释片,考察处方、工艺以及释放条件对体外释药行为的影响,解析其机理。方法以羟丙甲纤维素(HPMC)为骨架材料,乙基纤维素(EC)为阻滞剂,采用湿颗粒压片法制备奥沙西罗亲水凝胶骨架片,考察HPMC用量、HPMC黏度、EC用量、制备方法、压片压力、释放介质及转速对奥沙西罗骨架片体外释药的影响。结果奥沙西罗骨架片体外释药符合Higuchi方程,药物释放机制是骨架溶蚀和药物扩散的综合效应;HPMC用量与黏度、阻滞剂用量、制备方法、压片压力对释放速率均有显著性影响;释放介质的pH值及转速对释放速率无显著性影响。结论调整处方HPMC用量可制得12 h给药1次的骨架缓释片。 Purpose To prepare Oxaceprol delayed release matrix tablets, and to evaluate the effect of formula composition, preparation method and release conditions on the drug release behavior. Elucidating the mechanism of drug releasing. Methods Hydroxypropyl methylcellulose (HPMC) as matrix material, preparation by wet method compression. Investigating the pharmaceutical properties by dissolution test. Evaluating the amount and viscosity of HPMC, varieties and amount of blocking agents,the pH of dissolution medium and the speed of basket rotation effect on the drug release behavior. Optimizing the formula. Results The release behavior of Oxaceprol matrix tablets is following Higuchi equation, and is mainly affected by amount of HPMC. The releasing mechanism was in line with synthetical effect of dissolution and corrosion. Conclusion Amount of HPMC is the mainly influencing factor of Oxaceprol matrix tablet releasing. We could get a 12 h-lag tablet, in a certain formula composition.
机构地区 山东大学药学院
出处 《中国生化药物杂志》 CAS CSCD 2008年第3期175-178,共4页 Chinese Journal of Biochemical Pharmaceutics
基金 山东大学本科生创新基金立项课题
关键词 奥沙西罗 羟丙基甲基纤维素 骨架片 缓释 Oxaceprol Hydroxypropyl methylcellulose (HPMC) matrix tablets delayed release
  • 相关文献

参考文献6

二级参考文献23

共引文献107

同被引文献31

  • 1郭青梅,郭伟,程素芳.左氧氟沙星的临床应用[J].现代中西医结合杂志,2005,14(22):3024-3024. 被引量:15
  • 2罗京京,何玲,刘国卿.治疗阿尔茨海默病新药盐酸美金刚[J].中国新药杂志,2006,15(9):742-744. 被引量:24
  • 3黄桂华,王荣梅,王德风,张志文,邓树海.琥珀酸美托洛尔HPMC骨架片释放影响因素研究[J].生物医学工程学杂志,2006,23(3):587-591. 被引量:5
  • 4顾纪锋,张娜,席延卫,李林军,黄桂华.富马酸美托洛尔爆破型脉冲片体外实验研究[J].中国药学杂志,2006,41(20):1560-1564. 被引量:7
  • 5中国药典.二部[S].2010:凡例ⅩⅦ.
  • 6Ionac M,Parnham M J,Plauchchithiu M,et al.Oxaceprol,an atypi-cal inhibitor of inflammation and joint damage[J].Pharm Res,1996,33(6):367-373.
  • 7Bauer H W,Klasser M,von Hanstein K L,et al.Oxaceprol is as ef-fective as diclofenac in the therapy of osteoarthritis of the knee andhip[J].Clin Rheumatol,1999,18(1):4-9.
  • 8Sriamornsak P,Thirawong N,Weerapol Y,et al.Swelling and ero-sion of pectin matrix tablets and their impact on drug release be-havior[J].Eur J Pharm Biopharm,2007,67(1):211-219.
  • 9Ritger P L,Peppas N A.A simple equation for description of solutereleaseⅠ.Fickian and non-fckian release from non-swellable de-vices in the form of slabs,spheres,cylinders or discs[J].J Con-trolled Release,1987,5(1):23-26.
  • 10唐星.口服缓控释制剂[M].北京:人民卫生出版社.2006:3.

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部